IDH 1 & IDH2 GENE MUTATION - FFPE TISSUE

IDH1 & IDH2 Gene Mutation – FFPE Tissue Test

The IDH1 & IDH2 Gene Mutation – FFPE Tissue Test is an advanced molecular pathology diagnostic test used to detect mutations in the Isocitrate Dehydrogenase 1 (IDH1) and Isocitrate Dehydrogenase 2 (IDH2) genes using FFPE (Formalin-Fixed Paraffin-Embedded) tissue samples.

IDH gene mutations are important biomarkers commonly associated with brain tumors such as gliomas, acute myeloid leukemia (AML), chondrosarcoma, and other cancers. Identifying these mutations helps pathologists accurately classify tumors, determine prognosis, and guide targeted treatment planning.

This test is performed on preserved tissue samples collected during biopsy or surgery. The DNA is extracted from FFPE tissue and analyzed using advanced molecular techniques to identify clinically significant mutations in the IDH1 and IDH2 genes.

Detection of IDH mutations provides valuable diagnostic and prognostic information, helping oncologists select personalized therapies and predict treatment response.

Benefits of the Test

• Detects important cancer-related gene mutations
• Supports accurate tumor classification
• Helps guide targeted therapy decisions
• Assists prognosis evaluation
• Supports personalized oncology care
• Improves treatment planning precision

Why Doctors Recommend This Test

Doctors commonly recommend the IDH1 & IDH2 Gene Mutation Test when:

• Glioma or brain tumor is suspected
• Leukemia diagnosis requires molecular profiling
• Tumor classification needs confirmation
• Personalized cancer treatment planning is required
• Prognosis assessment is needed
• Cancer recurrence monitoring is required
• Histopathology suggests molecular testing
• Advanced oncology evaluation is necessary

This test helps ensure evidence-based precision medicine decisions.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE tissue block or unstained slides
• Previous pathology report submission
• Relevant medical records if available
• Ensure proper sample labeling
• Follow laboratory sample submission guidelines

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for the IDH1 & IDH2 Gene Mutation Test is usually 7–10 working days, depending on molecular processing complexity.

Who Should Take This Test?

This test is recommended for:

• Patients with glioma or suspected brain tumors
• Individuals diagnosed with AML
• Patients needing tumor molecular classification
• Individuals requiring targeted therapy planning
• Oncology patients under specialist care
• Patients requiring advanced molecular diagnosis

At Focus Diagnostics Hyderabad, advanced molecular pathology technology and expert specialists ensure highly accurate IDH1 & IDH2 mutation analysis reports for reliable diagnosis and personalized cancer treatment planning.